From: Electrochemotherapy: from the drawing board into medical practice
Drug tested | In vitro potentiation | In vivo potentiation |
---|---|---|
Bleomycin | Yes; 100–5000-fold [1, 17, 18, 26–28] | Yes |
Cisplatin | Yes; 1.8–12.2-fold [17, 18, 28, 29] | Yes [28–30] |
Calcium | Yes; more hundred-fold [31, 32] | Yes [31] |
Netropsin | Yes; 200-fold [1] | – |
Carboplatin | Yes; 1.6–13-fold [17, 18, 27, 29] | – |
2-N-methyl-9-hydroxy-ellipticinium (NMHE) | Yes; 4-fold [1] | – |
Vincristine | Yes; 1.3–3.4-fold [18] | – |
ActiNomycin D | Yes; 2–3-fold [1] | – |
Cytarabine | Yes; 2-fold [18] | – |
Oxaliplatin | Yes [29] | – |
Platinum (II) complex 3P-SK | Yes [29] | Yes [29] |
Platinum (II) complex PtAMP | Yes [29] | – |
Mitomycin C | Yes but low; 1.3–1.4-fold [18, 33] | – |
Vinblastine | Yes but low; 1.1–1.3-fold [18] | – |
5-fluorouracil | No or low; 1.25-fold [18, 26] | – |
Paclitaxel | No or low; 1.3-fold [17, 18] | – |
Doxorubicin | No or low; 0.67–2-fold [17, 18] | – |
Nimustine hydrochloride (ACNU) | No [27] | – |
Methotrexate | No [1] | – |
9-OH-ellipticine | No [1] | – |
Didemnin B | No [1] | – |
Melphalan | No [1] | – |
Mithramycin | No [1] | – |
Taxotere | No [1] | – |
DauNorubicin | No [17] | – |
Adriamycin | No [32] | No [28] |
Etoposide | No or ND [17, 18, 27] | – |
Ancitabine | ND [18] | – |
Gemcitabine | ND [18] | – |